352 related articles for article (PubMed ID: 23231486)
1. Developing oral probiotics from Streptococcus salivarius.
Wescombe PA; Hale JD; Heng NC; Tagg JR
Future Microbiol; 2012 Dec; 7(12):1355-71. PubMed ID: 23231486
[TBL] [Abstract][Full Text] [Related]
2. Interferon Gamma Response in Human Saliva Following Exposure to the Oral Probiotic Streptococcus salivarius BLIS K12.
Laws GA; Harold LK; Tagg JR; Hale JDF
Probiotics Antimicrob Proteins; 2024 Feb; 16(1):93-98. PubMed ID: 36477439
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral malodour.
Masdea L; Kulik EM; Hauser-Gerspach I; Ramseier AM; Filippi A; Waltimo T
Arch Oral Biol; 2012 Aug; 57(8):1041-7. PubMed ID: 22405584
[TBL] [Abstract][Full Text] [Related]
4. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters.
Burton JP; Chilcott CN; Moore CJ; Speiser G; Tagg JR
J Appl Microbiol; 2006 Apr; 100(4):754-64. PubMed ID: 16553730
[TBL] [Abstract][Full Text] [Related]
5. Influence of Oral Probiotic Streptococcus salivarius K12 on Ear and Oral Cavity Health in Humans: Systematic Review.
Zupancic K; Kriksic V; Kovacevic I; Kovacevic D
Probiotics Antimicrob Proteins; 2017 Jun; 9(2):102-110. PubMed ID: 28236205
[TBL] [Abstract][Full Text] [Related]
6. Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model.
Ishijima SA; Hayama K; Burton JP; Reid G; Okada M; Matsushita Y; Abe S
Appl Environ Microbiol; 2012 Apr; 78(7):2190-9. PubMed ID: 22267663
[TBL] [Abstract][Full Text] [Related]
7. Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract.
Bidossi A; De Grandi R; Toscano M; Bottagisio M; De Vecchi E; Gelardi M; Drago L
BMC Infect Dis; 2018 Dec; 18(1):653. PubMed ID: 30545317
[TBL] [Abstract][Full Text] [Related]
8. The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics.
Burton JP; Chilcott CN; Tagg JR
Oral Dis; 2005; 11 Suppl 1():29-31. PubMed ID: 15752094
[TBL] [Abstract][Full Text] [Related]
9. Beneficial microbes for the oral cavity: time to harness the oral streptococci?
Burton JP; Wescombe PA; Cadieux PA; Tagg JR
Benef Microbes; 2011 Jun; 2(2):93-101. PubMed ID: 21840808
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults.
Di Pierro F; Adami T; Rapacioli G; Giardini N; Streitberger C
Expert Opin Biol Ther; 2013 Mar; 13(3):339-43. PubMed ID: 23286823
[TBL] [Abstract][Full Text] [Related]
11. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction.
Horz HP; Meinelt A; Houben B; Conrads G
Oral Microbiol Immunol; 2007 Apr; 22(2):126-30. PubMed ID: 17311636
[TBL] [Abstract][Full Text] [Related]
12. Safety assessment of
Hale JDF; Jain R; Wescombe PA; Burton JP; Simon RR; Tagg JR
Benef Microbes; 2022 Feb; 13(1):47-60. PubMed ID: 35098909
[TBL] [Abstract][Full Text] [Related]
13. Probiotics: contributions to oral health.
Meurman JH; Stamatova I
Oral Dis; 2007 Sep; 13(5):443-51. PubMed ID: 17714346
[TBL] [Abstract][Full Text] [Related]
14. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children.
Di Pierro F; Colombo M; Giuliani MG; Danza ML; Basile I; Bollani T; Conti AM; Zanvit A; Rottoli AS
Eur Rev Med Pharmacol Sci; 2016 Nov; 20(21):4601-4606. PubMed ID: 27874935
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Streptococcus salivarius K12 on Halitosis: a Double-Blind, Randomized, Placebo-Controlled Trial.
He L; Yang H; Chen Z; Ouyang X
Probiotics Antimicrob Proteins; 2020 Dec; 12(4):1321-1329. PubMed ID: 32227309
[TBL] [Abstract][Full Text] [Related]
16. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics.
Wescombe PA; Heng NC; Burton JP; Chilcott CN; Tagg JR
Future Microbiol; 2009 Sep; 4(7):819-35. PubMed ID: 19722837
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study.
Burton JP; Cowley S; Simon RR; McKinney J; Wescombe PA; Tagg JR
Food Chem Toxicol; 2011 Sep; 49(9):2356-64. PubMed ID: 21722694
[TBL] [Abstract][Full Text] [Related]
18. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12.
Burton JP; Wescombe PA; Moore CJ; Chilcott CN; Tagg JR
Appl Environ Microbiol; 2006 Apr; 72(4):3050-3. PubMed ID: 16598017
[TBL] [Abstract][Full Text] [Related]
19. Bacterial replacement therapy: adapting 'germ warfare' to infection prevention.
Tagg JR; Dierksen KP
Trends Biotechnol; 2003 May; 21(5):217-23. PubMed ID: 12727383
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic effects of Streptococcus and Lactobacillus probiotics in pharyngeal biofilms.
Humphreys GJ; McBain AJ
Lett Appl Microbiol; 2019 Apr; 68(4):303-312. PubMed ID: 30776138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
